Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer.

Breast Cancer Res · 2026 · PMC12918290 · PMID 41572375

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

The combination of imlunestrant and abemaciclib did not demonstrate a confirmed OS benefit (HR 0.82; 95% CI, 0.59–1.16), but a favorable trend was observed [ 12 ].

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.